Baclofen treatment in Tourette syndrome

Harvey S. Singer · John T Wendlandt · Madeline Krieger · Joseph D. Giuliano

139 citations0/0 files storedNeurology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Obsessive-Compulsive Spectrum Disorders Schizophrenia research and treatment Stuttering Research and Treatment

Abstract

OBJECTIVE: To investigate the effectiveness of baclofen for the treatment of tics in children with Tourette syndrome (TS). BACKGROUND: Baclofen, which contains both gamma-aminobutyric acid (GABA) and phenylethylamine moieties, was suggested in an open-label protocol to be an effective treatment for TS. This is a double-blind, placebo-controlled study to investigate this medication in children with TS. METHODS: Subjects received, in a randomized sequence, 4-week medication cycles of baclofen (20 mg three times daily) and placebo with a 2-week intervening washout period between the cycles. Outcome measures included the Clinical Global Impression (CGI) scale, and the Yale Global Tic Severity Scale (YGTSS), the latter including subscales for total tics and overall impairment. Measures were assessed at baseline and on days 28, 42, and 70 of the study. RESULTS: Ten children (seven boys and three girls, aged 8 to 14) with TS participated. Nine subjects completed the protocol; one dropped out for psychosocial reasons. No major side effects were reported. The mean change in CGI score (-0.9) after 4 weeks of baclofen treatment as compared with placebo treatment showed a significant improvement (95% CI, -1.7 to -0.1; p = 0.04). All subjects showed some amelioration in total YGTSS score during baclofen treatment. The mean change in total YGTSS score (-14.7) approached significance (95% CI, -30.3 to 0.9; p = 0.06). Examination of differences between baclofen and placebo treatment groups expressed as a percent change from baseline showed that baclofen had a statistically significant effect on both outcome measures. Subscales of the YGTSS showed that the reduction in total tic scores was primarily due to a reduction in the impairment score rather than a decrease in tics. CONCLUSIONS: Children with TS may benefit from treatment with baclofen, although improvements may be related to factors other than tics. Larger studies directly comparing baclofen against other tic-suppressing agents are recommended.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 139 citations exist upstream.

References

1989The Yale Global Tic Severity Scale: Initial Testing of a Clinician-Rated Scale of Tic Severity 2000Tourette syndrome, associated conditions and the complexities of treatment 1998Course of Tic Severity in Tourette Syndrome: The First Two Decades 1989Controlled Study of Haloperidol, Pimozide, and Placebo for the Treatment of Gilles de la Tourette's Syndrome 1991Clonidine Treatment of Gilles de la Tourette's Syndrome 1987Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methods

Cited by

2018Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome 2010Treatment of Tics and Tourette Syndrome 2019Tics and Tourette Syndrome 2016Practitioner Review: Treatments for Tourette syndrome in children and young people – a systematic review 2014Tics and Tourette Syndrome 2002Neuropsychiatric Effects of Guanfacine in Children With Mild Tourette Syndrome: A Pilot Study 2008The management of tics

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.